trending Market Intelligence /marketintelligence/en/news-insights/trending/WU2QhMrSoE5LfrV6upO9IQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US Patent Office turns down Alvogen challenge for Celgene cancer drug Revlimid

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US Patent Office turns down Alvogen challenge for Celgene cancer drug Revlimid

The U.S. Patent and Trademark Office rejected Alvogen Pine Brook LLC's request for a review of the patents on Celgene Corp.'s blood cancer drug Revlimid, Reuters reported.

Pine Brook, N.J.-based Alvogen's filing challenging the validity of Revlimid's patents was turned down by the Patent Trial and Appeal Board, a court overseen by the patent office.

The court's rejection follows Alvogen Inc.'s launch of generic of Revlimid in the EU on Feb. 12.

Revlimid accounted for more than 60% of the Summit, N.J.-based Celgene's overall sales in 2018, about $9.69 billion, an 18% increase from 2017. The drug is approved in the U.S. for patients with multiple myeloma and myelodysplastic syndrome who need transfusions to replace blood cells and for those with mantle cell lymphoma that has progressed or relapsed after two treatments.

The therapy is being reviewed by the U.S. Food and Drug Administration in combination with Roche Holding AG's Rituxan for treating patients with follicular and marginal zone lymphoma whose disease returned or did not respond to initial treatment.

Bristol-Myers Squibb Co. in January started a $74 billion takeover of Celgene, with executives saying Revlimid made the deal more compelling. The drug is facing imminent generic competition, but Bristol-Myers executives dismissed concerns about sales erosion, telling investors that Revlimid will continue to be a valuable asset for the combined company.